pillbase.ru

BLINCYTO

Active substance: blinatumomab

KIT · blinatumomab

United StatesActive

Marketing holder: Amgen, Inc

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
RU 2
  • Блинцито
    порошок для приготовления концентрата для приготовления раствора для инфузий, 35 мкг, 35 мкг (original in Russian, GRLS)
    ЛП-004035
    Амджен Европа Б.В.
  • Блинцито®
    лиофилизат для приготовления концентрата для приготовления раствора для инфузий, 35 мкг, 35 мкг (original in Russian, GRLS)
    ЛП-№(002210)-(РГ-RU)
    Амджен Европа Б.В.
EU 1
  • Blincyto
    blinatumomab
    EMEA/H/C/003731
    Amgen Europe B.V.
Import and control

Control by country

  • Russiaprescription only

    Source: GRLS (Russian state register) · record 01a120c3-4778-7f78-8eaa-d213353b7462,01a120c5-bbe8-7700-978c-d65610098e70;count=2 · valid from 2026-10-09 · verified 2026-10-09

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208d-4551-735b-bd90-eb67d8fb072b;count=1 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
55513-160
Registration status
Active
Dispensing
Prescription only
Sources
  • product · openFDA NDC · 55513-160 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 55513-160 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 55513-160 · Verified 2026-10-09 · open in source